All eyes on Supreme Court as it weighs Myriad's gene patents

In August, Myriad Genetics ($MYGN) won an appeals court affirmation of its rights to patent isolated genes related to cancer, but today the Supreme Court will take up the issue of whether intellectual property stretches all the way to the genetic code. Opponents argue that the patents give Myriad a monopoly in certain diagnostic testing markets, unfairly allowing the company to capitalize on what is part of the human body. Meanwhile, industry supporters caution that nullifying Myriad's patents would severely hamstring a beneficial wing of scientific research. More

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.